Nasdaq · CIK 0001425205
IOVA IOVANCE BIOTHERAPEUTICS, INC.
Insider trading from SEC Form 4. Last filing 10 d ago. Close $14.62 on Oct 9, 2026, +708% from the 52-week low and -1% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
10
with a Form 4 at this company
Price and insider trades, last year
IOVAOct 9, 2026 · close 14.62
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at IOVANCE BIOTHERAPEUTICS, INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 56Moderate | Daniel Gordon Kirby Chief Commercial Officer buy | $55k 30,000 shares | - | +8% from low-85% from high | |
| 48Moderate | Raj K. Puri Chief Regulatory Officer buy | $9,743 5,600 shares | +3% | +7% from low-86% from high | |
| 60Notable | Frederick G Vogt Interim CEO & General Counsel buy | $42k 25,000 shares | +7% | 0% from low-86% from high | |
| 38Weak | Ryan D Maynard director sell | $503k 50,000 shares | -87% | - |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | Noah Berkowitz Chief Medical Officer | AGrant or award Stock Options (Right to Buy)derivative | +135,000 | $0.00 | $0 | 135,000 | 10 d ago |
| Sep 30, 2026 | Noah Berkowitz Chief Medical Officer | AGrant or award Restricted Stock Unitsderivative | +180,000 | $0.00 | $0 | 180,000 | 10 d ago |
| Sep 30, 2026 | Noah Berkowitz Chief Medical Officer | AGrant or award Performance Stock Unitsderivative | +135,000 | $0.00 | $0 | 135,000 | 10 d ago |
| Sep 8, 2026 | Raj K. Puri Chief Regulatory Officer | MOption exercise Common Stock | +9,766 | $0.00 | $0 | 260,842 | 32 d ago |
| Sep 8, 2026 | Igor Bilinsky Chief Operating Officer | MOption exercise Common Stock | +7,813 | $0.00 | $0 | 146,050 | 32 d ago |
| Sep 8, 2026 | Frederick G Vogt Interim CEO & General Counsel | MOption exercise Common Stock | +15,626 | $0.00 | $0 | 602,085 | 32 d ago |
| Sep 8, 2026 | Raj K. Puri Chief Regulatory Officer | FTax withholding Common Stock | -4,478 | $8.70 | $39k | 256,364 | 32 d ago |
| Sep 8, 2026 | Igor Bilinsky Chief Operating Officer | FTax withholding Common Stock | -3,976 | $8.70 | $35k | 142,074 | 32 d ago |
| Sep 8, 2026 | Frederick G Vogt Interim CEO & General Counsel | FTax withholding Common Stock | -6,638 | $8.70 | $58k | 595,447 | 32 d ago |
| Sep 8, 2026 | Igor Bilinsky Chief Operating Officer | MOption exercise Restricted Stock Unitsderivative | -7,813 | $0.00 | $0 | 46,878 | 32 d ago |
| Sep 8, 2026 | Frederick G Vogt Interim CEO & General Counsel | MOption exercise Restricted Stock Unitsderivative | -15,626 | $0.00 | $0 | 93,756 | 32 d ago |
| Sep 8, 2026 | Raj K. Puri Chief Regulatory Officer | MOption exercise Restricted Stock Unitsderivative | -9,766 | $0.00 | $0 | 58,599 | 32 d ago |
| Sep 1, 2026 | Raj K. Puri Chief Regulatory Officer | MOption exercise Common Stock | +5,470 | $0.00 | $0 | 253,584 | 39 d ago |
| Sep 1, 2026 | Igor Bilinsky Chief Operating Officer | MOption exercise Common Stock | +8,789 | $0.00 | $0 | 142,709 | 39 d ago |
| Sep 1, 2026 | Frederick G Vogt Interim CEO & General Counsel | MOption exercise Common Stock | +41,669 | $0.00 | $0 | 604,161 | 39 d ago |
| Sep 1, 2026 | Raj K. Puri Chief Regulatory Officer | FTax withholding Common Stock | -2,508 | $8.28 | $21k | 251,076 | 39 d ago |
| Sep 1, 2026 | Igor Bilinsky Chief Operating Officer | FTax withholding Common Stock | -4,472 | $8.28 | $37k | 138,237 | 39 d ago |
| Sep 1, 2026 | Frederick G Vogt Interim CEO & General Counsel | FTax withholding Common Stock | -17,702 | $8.28 | $147k | 586,459 | 39 d ago |
| Sep 1, 2026 | Raj K. Puri Chief Regulatory Officer | MOption exercise Restricted Stock Unitsderivative | -5,470 | $0.00 | $0 | 10,939 | 39 d ago |
| Sep 1, 2026 | Frederick G Vogt Interim CEO & General Counsel | MOption exercise Restricted Stock Unitsderivative | -41,669 | $0.00 | $0 | 83,338 | 39 d ago |
| Sep 1, 2026 | Igor Bilinsky Chief Operating Officer | MOption exercise Restricted Stock Unitsderivative | -8,789 | $0.00 | $0 | 17,580 | 39 d ago |
| Mar 9, 2026 | Daniel Gordon Kirby Chief Commercial Officer | AGrant or award Restricted Stock Unitsderivative | +132,200 | $0.00 | $0 | 132,200 | Mar 11, 2026 |
| Mar 9, 2026 | Igor Bilinsky Chief Operating Officer | AGrant or award Restricted Stock Unitsderivative | +117,500 | $0.00 | $0 | 117,500 | Mar 11, 2026 |
| Mar 9, 2026 | Finckenstein Friedrich Graf Chief Medical Officer | AGrant or award Restricted Stock Unitsderivative | +58,750 | $0.00 | $0 | 58,750 | Mar 11, 2026 |
| Mar 9, 2026 | Raj K. Puri Chief Regulatory Officer | AGrant or award Restricted Stock Unitsderivative | +117,500 | $0.00 | $0 | 117,500 | Mar 11, 2026 |
| Mar 9, 2026 | Frederick G Vogt Interim CEO & General Counsel | AGrant or award Restricted Stock Unitsderivative | +235,000 | $0.00 | $0 | 235,000 | Mar 11, 2026 |
| Mar 9, 2026 | Corleen M. Roche Chief Financial Officer | AGrant or award Restricted Stock Unitsderivative | +132,200 | $0.00 | $0 | 132,200 | Mar 11, 2026 |
| Mar 5, 2026 | Raj K. Puri Chief Regulatory Officer | MOption exercise Common Stock | +39,059 | $0.00 | $0 | 257,590 | Mar 6, 2026 |
| Mar 5, 2026 | Frederick G Vogt Interim CEO & General Counsel | MOption exercise Common Stock | +62,493 | $0.00 | $0 | 556,293 | Mar 6, 2026 |
| Mar 5, 2026 | Igor Bilinsky Chief Operating Officer | MOption exercise Common Stock | +31,246 | $0.00 | $0 | 142,394 | Mar 6, 2026 |
| Mar 5, 2026 | Finckenstein Friedrich Graf Chief Medical Officer | MOption exercise Common Stock | +31,246 | $0.00 | $0 | 148,477 | Mar 6, 2026 |
| Mar 5, 2026 | Finckenstein Friedrich Graf Chief Medical Officer | FTax withholding Common Stock | -16,520 | $4.58 | $76k | 131,957 | Mar 6, 2026 |
| Mar 5, 2026 | Frederick G Vogt Interim CEO & General Counsel | FTax withholding Common Stock | -26,755 | $4.58 | $123k | 529,538 | Mar 6, 2026 |
| Mar 5, 2026 | Raj K. Puri Chief Regulatory Officer | FTax withholding Common Stock | -18,360 | $4.58 | $84k | 239,230 | Mar 6, 2026 |
| Mar 5, 2026 | Igor Bilinsky Chief Operating Officer | FTax withholding Common Stock | -16,628 | $4.58 | $76k | 125,766 | Mar 6, 2026 |
| Mar 5, 2026 | Frederick G Vogt Interim CEO & General Counsel | MOption exercise Restricted Stock Unitsderivative | -62,493 | $0.00 | $0 | 125,007 | Mar 6, 2026 |
| Mar 5, 2026 | Finckenstein Friedrich Graf Chief Medical Officer | MOption exercise Restricted Stock Unitsderivative | -31,246 | $0.00 | $0 | 62,504 | Mar 6, 2026 |
| Mar 5, 2026 | Raj K. Puri Chief Regulatory Officer | MOption exercise Restricted Stock Unitsderivative | -39,059 | $0.00 | $0 | 78,131 | Mar 6, 2026 |
| Mar 5, 2026 | Igor Bilinsky Chief Operating Officer | MOption exercise Restricted Stock Unitsderivative | -31,246 | $0.00 | $0 | 62,504 | Mar 6, 2026 |
| Mar 2, 2026 | Igor Bilinsky Chief Operating Officer | MOption exercise Common Stock | +12,307 | $0.00 | $0 | 118,051 | Mar 4, 2026 |
| Mar 2, 2026 | Finckenstein Friedrich Graf Chief Medical Officer | MOption exercise Common Stock | +12,697 | $0.00 | $0 | 124,353 | Mar 4, 2026 |
| Mar 2, 2026 | Raj K. Puri Chief Regulatory Officer | MOption exercise Common Stock | +5,470 | $0.00 | $0 | 221,329 | Mar 4, 2026 |
| Mar 2, 2026 | Frederick G Vogt Interim CEO & General Counsel | MOption exercise Common Stock | +52,087 | $0.00 | $0 | 516,609 | Mar 4, 2026 |
| Mar 2, 2026 | Igor Bilinsky Chief Operating Officer | FTax withholding Common Stock | -6,903 | $3.79 | $26k | 111,148 | Mar 4, 2026 |
| Mar 2, 2026 | Finckenstein Friedrich Graf Chief Medical Officer | FTax withholding Common Stock | -7,122 | $3.79 | $27k | 117,231 | Mar 4, 2026 |
| Mar 2, 2026 | Raj K. Puri Chief Regulatory Officer | FTax withholding Common Stock | -2,798 | $3.79 | $11k | 218,531 | Mar 4, 2026 |
| Mar 2, 2026 | Frederick G Vogt Interim CEO & General Counsel | FTax withholding Common Stock | -22,809 | $3.79 | $86k | 493,800 | Mar 4, 2026 |
| Mar 2, 2026 | Igor Bilinsky Chief Operating Officer | MOption exercise Restricted Stock Unitsderivative | -8,790 | $0.00 | $0 | 35,159 | Mar 4, 2026 |
| Mar 2, 2026 | Finckenstein Friedrich Graf Chief Medical Officer | MOption exercise Restricted Stock Unitsderivative | -8,790 | $0.00 | $0 | 35,159 | Mar 4, 2026 |
| Mar 2, 2026 | Raj K. Puri Chief Regulatory Officer | MOption exercise Restricted Stock Unitsderivative | -5,470 | $0.00 | $0 | 21,878 | Mar 4, 2026 |
| Mar 2, 2026 | Frederick G Vogt Interim CEO & General Counsel | MOption exercise Restricted Stock Unitsderivative | -41,669 | $0.00 | $0 | 166,675 | Mar 4, 2026 |
| Mar 2, 2026 | Igor Bilinsky Chief Operating Officer | MOption exercise Restricted Stock Unitsderivative | -3,517 | $0.00 | $0 | 0 | Mar 4, 2026 |
| Mar 2, 2026 | Finckenstein Friedrich Graf Chief Medical Officer | MOption exercise Restricted Stock Unitsderivative | -3,907 | $0.00 | $0 | 0 | Mar 4, 2026 |
| Mar 2, 2026 | Frederick G Vogt Interim CEO & General Counsel | MOption exercise Restricted Stock Unitsderivative | -10,418 | $0.00 | $0 | 0 | Mar 4, 2026 |
| Feb 24, 2026 | Daniel Gordon Kirby Chief Commercial Officer | MOption exercise Common Stock | +120,000 | $0.00 | $0 | 173,546 | Feb 26, 2026 |
| Feb 24, 2026 | Daniel Gordon Kirby Chief Commercial Officer | FTax withholding Common Stock | -34,165 | $3.78 | $129k | 139,381 | Feb 26, 2026 |
| Feb 24, 2026 | Daniel Gordon Kirby Chief Commercial Officer | MOption exercise Restricted Stock Unitsderivative | -150,000 | $0.00 | $0 | 0 | Feb 26, 2026 |
| Feb 10, 2026 | Daniel Gordon Kirby Chief Commercial Officer | MOption exercise Common Stock | +39,996 | $0.00 | $0 | 69,996 | Feb 12, 2026 |
| Feb 10, 2026 | Daniel Gordon Kirby Chief Commercial Officer | FTax withholding Common Stock | -16,450 | $2.60 | $43k | 53,546 | Feb 12, 2026 |
| Feb 10, 2026 | Daniel Gordon Kirby Chief Commercial Officer | MOption exercise Restricted Stock Unitsderivative | -39,996 | $0.00 | $0 | 80,004 | Feb 12, 2026 |
| Dec 1, 2025 | Igor Bilinsky Chief Operating Officer | MOption exercise Common Stock | +8,789 | $0.00 | $0 | 108,478 | Dec 3, 2025 |
| Dec 1, 2025 | Finckenstein Friedrich Graf Chief Medical Officer | MOption exercise Common Stock | +8,789 | $0.00 | $0 | 114,198 | Dec 3, 2025 |
| Dec 1, 2025 | Raj K. Puri Chief Regulatory Officer | MOption exercise Common Stock | +5,469 | $0.00 | $0 | 218,326 | Dec 3, 2025 |
| Dec 1, 2025 | Frederick G Vogt Interim CEO & General Counsel | MOption exercise Common Stock | +41,669 | $0.00 | $0 | 476,232 | Dec 3, 2025 |
| Dec 1, 2025 | Igor Bilinsky Chief Operating Officer | FTax withholding Common Stock | -4,464 | $2.23 | $9,955 | 104,014 | Dec 3, 2025 |
| Dec 1, 2025 | Finckenstein Friedrich Graf Chief Medical Officer | FTax withholding Common Stock | -4,464 | $2.23 | $9,955 | 109,734 | Dec 3, 2025 |
| Dec 1, 2025 | Raj K. Puri Chief Regulatory Officer | FTax withholding Common Stock | -2,467 | $2.23 | $5,501 | 215,859 | Dec 3, 2025 |
| Dec 1, 2025 | Frederick G Vogt Interim CEO & General Counsel | FTax withholding Common Stock | -17,701 | $2.23 | $39k | 458,531 | Dec 3, 2025 |
| Dec 2, 2025 | Finckenstein Friedrich Graf Chief Medical Officer | MOption exercise Common Stock | +3,906 | $0.00 | $0 | 113,640 | Dec 3, 2025 |
| Dec 2, 2025 | Frederick G Vogt Interim CEO & General Counsel | MOption exercise Common Stock | +10,417 | $0.00 | $0 | 468,948 | Dec 3, 2025 |
| Dec 1, 2025 | Raj K. Puri Chief Regulatory Officer | MOption exercise Restricted Stock Unitsderivative | -5,469 | $0.00 | $0 | 27,348 | Dec 3, 2025 |
| Dec 2, 2025 | Igor Bilinsky Chief Operating Officer | MOption exercise Common Stock | +3,516 | $0.00 | $0 | 107,530 | Dec 3, 2025 |
| Dec 2, 2025 | Finckenstein Friedrich Graf Chief Medical Officer | FTax withholding Common Stock | -1,984 | $2.14 | $4,246 | 111,656 | Dec 3, 2025 |
| Dec 2, 2025 | Frederick G Vogt Interim CEO & General Counsel | FTax withholding Common Stock | -4,426 | $2.14 | $9,472 | 464,522 | Dec 3, 2025 |
| Dec 2, 2025 | Igor Bilinsky Chief Operating Officer | FTax withholding Common Stock | -1,786 | $2.14 | $3,822 | 105,744 | Dec 3, 2025 |
| Dec 1, 2025 | Igor Bilinsky Chief Operating Officer | MOption exercise Restricted Stock Unitsderivative | -8,789 | $0.00 | $0 | 43,949 | Dec 3, 2025 |
| Dec 1, 2025 | Finckenstein Friedrich Graf Chief Medical Officer | MOption exercise Restricted Stock Unitsderivative | -8,789 | $0.00 | $0 | 43,949 | Dec 3, 2025 |
| Dec 1, 2025 | Frederick G Vogt Interim CEO & General Counsel | MOption exercise Restricted Stock Unitsderivative | -41,669 | $0.00 | $0 | 208,344 | Dec 3, 2025 |
| Dec 2, 2025 | Finckenstein Friedrich Graf Chief Medical Officer | MOption exercise Restricted Stock Unitsderivative | -3,906 | $0.00 | $0 | 3,907 | Dec 3, 2025 |
| Dec 2, 2025 | Frederick G Vogt Interim CEO & General Counsel | MOption exercise Restricted Stock Unitsderivative | -10,417 | $0.00 | $0 | 10,418 | Dec 3, 2025 |
| Dec 2, 2025 | Igor Bilinsky Chief Operating Officer | MOption exercise Restricted Stock Unitsderivative | -3,516 | $0.00 | $0 | 3,517 | Dec 3, 2025 |
| Sep 2, 2025 | Igor Bilinsky Chief Operating Officer | MOption exercise Common Stock | +12,306 | $0.00 | $0 | 105,939 | Sep 4, 2025 |
| Sep 2, 2025 | Finckenstein Friedrich Graf Chief Medical Officer | MOption exercise Common Stock | +12,697 | $0.00 | $0 | 111,857 | Sep 4, 2025 |
| Sep 2, 2025 | Raj K. Puri Chief Regulatory Officer | MOption exercise Common Stock | +5,470 | $0.00 | $0 | 215,324 | Sep 4, 2025 |
| Sep 2, 2025 | Frederick G Vogt Interim CEO & General Counsel | MOption exercise Common Stock | +52,086 | $0.00 | $0 | 456,690 | Sep 4, 2025 |
| Sep 2, 2025 | Igor Bilinsky Chief Operating Officer | FTax withholding Common Stock | -6,250 | $2.19 | $14k | 99,689 | Sep 4, 2025 |
| Sep 2, 2025 | Finckenstein Friedrich Graf Chief Medical Officer | FTax withholding Common Stock | -6,448 | $2.19 | $14k | 105,409 | Sep 4, 2025 |
| Sep 2, 2025 | Raj K. Puri Chief Regulatory Officer | FTax withholding Common Stock | -2,467 | $2.19 | $5,403 | 212,857 | Sep 4, 2025 |
| Sep 2, 2025 | Frederick G Vogt Interim CEO & General Counsel | FTax withholding Common Stock | -22,127 | $2.19 | $48k | 434,563 | Sep 4, 2025 |
| Sep 2, 2025 | Igor Bilinsky Chief Operating Officer | MOption exercise Restricted Stock Unitsderivative | -3,516 | $0.00 | $0 | 7,033 | Sep 4, 2025 |
| Sep 2, 2025 | Finckenstein Friedrich Graf Chief Medical Officer | MOption exercise Restricted Stock Unitsderivative | -3,907 | $0.00 | $0 | 7,813 | Sep 4, 2025 |
| Sep 2, 2025 | Raj K. Puri Chief Regulatory Officer | MOption exercise Restricted Stock Unitsderivative | -5,470 | $0.00 | $0 | 32,817 | Sep 4, 2025 |
| Sep 2, 2025 | Frederick G Vogt Interim CEO & General Counsel | MOption exercise Restricted Stock Unitsderivative | -10,417 | $0.00 | $0 | 20,385 | Sep 4, 2025 |
| Sep 2, 2025 | Igor Bilinsky Chief Operating Officer | MOption exercise Restricted Stock Unitsderivative | -8,790 | $0.00 | $0 | 52,738 | Sep 4, 2025 |
| Sep 2, 2025 | Finckenstein Friedrich Graf Chief Medical Officer | MOption exercise Restricted Stock Unitsderivative | -8,790 | $0.00 | $0 | 52,738 | Sep 4, 2025 |
| Sep 2, 2025 | Frederick G Vogt Interim CEO & General Counsel | MOption exercise Restricted Stock Unitsderivative | -41,669 | $0.00 | $0 | 250,013 | Sep 4, 2025 |
| Aug 6, 2025 | Corleen M. Roche Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +300,000 | $0.00 | $0 | 300,000 | Aug 8, 2025 |
| Aug 6, 2025 | Corleen M. Roche Chief Financial Officer | AGrant or award Restricted Stock Unitsderivative | +150,000 | $0.00 | $0 | 150,000 | Aug 8, 2025 |
| Jun 13, 2025 | Athena Countouriotis director | AGrant or award Deferred Restricted Stock Unitderivative | +67,546 | $0.00 | $0 | 67,546 | Jun 17, 2025 |
| Jun 13, 2025 | Iain D. Dukes director | AGrant or award Deferred Restricted Stock Unitderivative | +135,092 | $0.00 | $0 | 135,092 | Jun 17, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Igor BilinskyChief Operating Officer
- Noah BerkowitzChief Medical Officer
- Athena Countouriotisdirector
- Iain D. Dukesceo, chair, officer, director
- Finckenstein Friedrich GrafChief Medical Officer
- Daniel Gordon KirbyChief Commercial Officer
- Ryan D Maynarddirector, cfo, officer
- Raj K. PuriChief Regulatory Officer
- Corleen M. RocheChief Financial Officer
- Frederick G VogtInterim CEO & General Counsel
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.